pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5 catalysts · 2 phase 2 completion · 1 phase 1 completion · 1 phase 2 initiation · 1 phase 2 results

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 17 catalysts2026-11-04: 22 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
TA: oncology×from 2026-04-26×to 2026-04-26×clear all
type
  • phase 2 completion2
  • phase 1 completion1
  • phase 2 initiation1
  • phase 2 results1
therapy area
  • Oncology5
Dermatology
5
  • Women's Health4
  • Immunology3
  • Cardiology3
  • Infectious Disease2
  • Ophthalmology2
  • Pulmonology2
  • Pain1
  • Week of Apr 20, 2026

    5
    ›Apr 26, 2026phase 1 completion107d agoPfizer Inc — PF-08046032 (Phase I Trial Completion)PF-08046032

    Therapy area: Oncology. Indication: Advanced Malignancy, Diffuse Large B-Cell Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Solid Tumor

    full page →PF-08046032 →source: globaldata
    ›Apr 26, 2026phase 2 completion107d agoAnyang Tumor Hospital — camrelizumab (Phase II Trial Completion)apatinib mesylate

    Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

    full page →apatinib mesylate →source: globaldata
    ›Apr 26, 2026phase 2 completion107d agoMemorial Sloan Kettering Cancer Center — iberdomide hydrochloride (Phase II Trial Completion)iberdomide hydrochloride

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease)

    full page →iberdomide hydrochloride →source: globaldata
    ›Apr 26, 2026phase 2 initiation107d agoBeijing StarMab BioMed Technology Ltd — SM-3321 (Phase II Trial Initiation)SM-3321

    Therapy area: Oncology. Indication: Advanced Malignancy, Solid Tumor

    full page →SM-3321 →source: globaldata
    ›Apr 26, 2026phase 2 results107d agoAllogene Therapeutics Inc — ALLO-647 (Phase II Trial Results)ALLO-647

    Therapy area: Oncology. Indication: Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma

    full page →ALLO-647 →source: globaldata
    $ALLO2.1000+4.48%
    $PFE27.05+1.08%